Compugen (CGEN)
(Delayed Data from NSDQ)
$1.93 USD
-0.05 (-2.53%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $1.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGEN 1.93 -0.05(-2.53%)
Will CGEN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Other News for CGEN
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen initiated with bullish view at William Blair
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen announces publication of peer reviewed paper on IL-18
Compugen to Participate in Two Upcoming Investor Conferences